Welcome to LookChem.com Sign In|Join Free
  • or
Flutamide, also known by its brand names Eulexin (Schering) and DROGENIL, is a synthetic, non-steroidal antiandrogen drug. It is a toluidine derivative with a similar structure to bicalutamide and nilutamide. Flutamide is characterized by its light yellow solid chemical property and is dosed three times daily in 250-mg doses, totaling a 750-mg daily dose. Its major metabolite, hydroxyflutamide, is a more potent androgen receptor (AR) antagonist than the parent compound and contributes significantly to the drug's antiandrogen action. Flutamide is mainly used for the treatment of prostate cancer and can also be used for hyperandrogenism in women, as well as a component in transgender hormone therapy.

13311-84-7

Post Buying Request

13311-84-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

13311-84-7 Usage

Uses

Used in Oncology:
Flutamide is used as an antiandrogen and antineoplastic (hormonal) agent for the treatment of prostate cancer in both castrates and noncastrates. It functions as a selective antagonist of the androgen receptor (AR), preventing androgens such as testosterone and its active metabolite dihydrotestosterone from binding to ARs in the prostate gland. This process inhibits androgen-dependent DNA and protein synthesis in the tumor cell, thereby preventing androgens from stimulating the growth of prostate cancer cells.
Used in Neurology:
Flutamide is also used as a neuroleptic, although its specific applications in this field are not detailed in the provided materials.
Used in Hyperandrogenism Treatment:
Besides prostate cancer, flutamide has been tested and/or used off-label for other hyperandrogenism-related disorders in women, such as benign prostatic hyperplasia, acne vulgaris, and hirsutism syndrome. It is effective in alleviating symptoms like acne, seborrhea, hirsutism, and androgenetic alopecia. However, due to its teratogenic potential, flutamide is restricted for premenopausal women and is used only in combination with effective contraception.
Limitations:
A limiting factor in the use of flutamide is hepatotoxicity, which occurs in 1% to 5% of patients. Although the hepatotoxicity is usually reversible following cessation of treatment, rare cases of death associated with hepatic failure have been reported in association with flutamide therapy. Additionally, diarrhea is a limiting side effect for some patients undergoing flutamide therapy.

References

https://en.wikipedia.org/wiki/Flutamide https://pubchem.ncbi.nlm.nih.gov/compound/flutamide#section=Top

Originator

scheting (USA)

History

Flutamide was first described as a member of a series of N-acyl anilides synthesized at Monsanto in the 1960s during a compound finding program aiming at bacteriostatic agents. Soon after, at Schering Corp., the compound was characterized pharmacologically and further developed as SCH-13521. It was found that flutamide inhibits agonist action at the AR by replacing the agonist at the ligand binding site, being the first nonsteroidal compound possessing anti-androgenic activity in animals. In contrast to steroidal anti-androgens, for instance, cyproterone acetate, which also displays significant progestational activity, flutamide has no other hormonal activity. There is also no reduction of serum testosterone levels seen with flutamide but rather a slight increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) resulting in elevated serum testosterone levels. This accounts for the beneficial maintenance of libido and potency in sexually active patients. On the other hand, elevated serum estradiol levels resulting from peripheral testosterone aromatization leading to gynecomastia were observed in patients.

Indications

Flutamide is a prodrug possessing only weak androgen antagonistic activity of its own. It is oxidized in vivo to the active principle hydroxyflutamide (6) as primary metabolite.The elimination half-life of hydroxyflutamide is relatively short, 4–6.6 h in patients after a single oral 250 mg dose of flutamide. Therefore, oral dosing of 250 mg flutamide three times daily was applied clinically. The first introduction into clinical studies was achieved in 1975 as single agent in the first-line treatment of advanced prostate carcinoma. In the United States, flutamide was finally approved by FDA in 1989 for the treatment of metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone (LHRH, also referred to as gonadotropin-releasing hormone (GnRH)) agonist, for instance, leuprorelin acetate (Leuprolide(R), Lupron(R)) or goserelin acetate (Zoladex(R)).The combined androgen blockade by flutamide plus an LHRH agonist or surgical castration was introduced in order to maximize the effects of androgen ablation. Flutamide also inhibits the secretion of androgens from the adrenal gland, which is not impaired by chemical castration with LHRH agonists or by surgical castration. In addition, the AR antagonist avoids the unacceptable initial tumor flare that occurs when LHRH agonists are given alone. Favorable response to flutamide was seen with advanced prostate carcinoma patients after single-agent treatment as well as after combination treatment. The progression of the disease was slowed and the lifetime of patients was extended. For instance, the National Cancer Institute (NCI) initiated a trial (INT-0036) and concluded that the combination of leuprolide with flutamide was more effective than leuprolide alone in patients with advanced prostate cancer. However, significant side effects were also reported.The most frequently observed adverse events are summarized in Table 1. Flutamide evidently amplifies some of the LHRH agonist-induced side effects. Table 1 Side effects of LHRH antagonist alone and in combination with flutamide.

Indications

Flutamide (Eulexin) is a nonsteroidal androgen receptor antagonist that inhibits androgen binding to its nuclear receptor. It is effective in inducing prostatic regression and is approved for the treatment of prostatic carcinoma. For maximum clinical effectiveness it has to be used in combination with a GnRH antagonist (e.g., leuprolide acetate) that inhibits androgen production. Flutamide may eventually be used for the treatment of hirsutism and male pattern baldness in women if a topical preparation is developed.

Indications

Flutamide (Eulexin) is a nonsteroidal antiandrogen compound that competes with testosterone for binding to androgen receptors. The drug is well absorbed on oral administration. It is an active agent in the hormonal therapy of cancer of the prostate and has been shown to complement the pharmacological castration produced by the gonadotropin-releasing hormone (GnRH) agonist leuprolide. Flutamide prevents the stimulation of tumor growth that may occur as a result of the transient increase in testosterone secretion after the initiation of leuprolide therapy. The most common side effects of flutamide are those expected with androgen blockade: hot flashes, loss of libido, and impotence. Mild nausea and diarrhea occur in about 10% of patients.

Manufacturing Process

To a stirred, cooled solution of 100 g of 4-nitro-3-trifluoromethylaniline in 400 ml of pyridine, slowly and in a dropwise fashion, add 54 g of isobutyrylchloride and then heat the reaction mixture on a steam bath for 1.5 hours. Cool and pour the resulting mixture into ice water, filter and waterwash the crude anilide and crystallize the product of this example from benzene to obtain analytically pure material, MP 111.5°C to 112.5°C.

Therapeutic Function

Antiandrogen

Biochem/physiol Actions

Flutamide is a non-steroidal anti-androgen drug. It consists of a nitroaromatic structure. Flutamide is a potent competitor of testosterone and dihydrotestosterone receptors. It is a potent hepatotoxin.

Contact allergens

Flutamide is an antiandrogenic hormonal antineoplas tic drug that can induce photosensitivity and porphy ria-like eruption.

Mechanism of action

Flutamide is a nonsteroid drug that possesses antiandrogenic action. It blocks androgens from binding with target tissues, thus preventing androgen action. The mechanism of action is possibly also linked with a halt in dihydrotestosterone transport. It facilitates a reduction in size and density of the prostate gland, and it reduces the amount of metastases in such cancer, for which it is used in palliative treatment of prostate gland cancer.

Clinical Use

Flutamide is a pure antagonist, whereas 2-hydroxyflutamide is a more potent AR antagonist but also can activate the androgenic receptor at higher concentrations. These findings raise the possibility that increased conversion of flutamide to 2-hydroxyflutamide or accumulation of 2-hydroxyflutamide in cells may contribute to the anomalous responses to flutamide that are observed in some advanced prostate cancers.

Synthesis

Flutamide, 4-nitro-3-trifluoromethylisobutyranilide (29.2.15), a nonsteroid antagonist of androgens, is made by acylating 4-nitro-3-trifluoromethylaniline with isobutyric acid chloride.

Drug interactions

Potentially hazardous interactions with other drugs Anticoagulants: effects of coumarins enhanced

Metabolism

It is rapidly and extensively metabolised; the major metabolite (2-hydroxyflutamide) possesses anti-androgenic properties. Both flutamide and 2-hydroxyflutamide are more than 90% bound to plasma proteins.Excretion is mainly in the urine with only minor amounts appearing in the faeces

Check Digit Verification of cas no

The CAS Registry Mumber 13311-84-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,3,1 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 13311-84:
(7*1)+(6*3)+(5*3)+(4*1)+(3*1)+(2*8)+(1*4)=67
67 % 10 = 7
So 13311-84-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H11F4NO/c1-6(2)10(17)16-7-3-4-9(12)8(5-7)11(13,14)15/h3-6H,1-2H3,(H,16,17)

13311-84-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (F0663)  Flutamide  >98.0%(GC)

  • 13311-84-7

  • 5g

  • 385.00CNY

  • Detail
  • TCI America

  • (F0663)  Flutamide  >98.0%(GC)

  • 13311-84-7

  • 25g

  • 1,150.00CNY

  • Detail
  • Sigma-Aldrich

  • (F0285600)  Flutamide  European Pharmacopoeia (EP) Reference Standard

  • 13311-84-7

  • F0285600

  • 1,880.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0001591)  Flutamide for system suitability  European Pharmacopoeia (EP) Reference Standard

  • 13311-84-7

  • Y0001591

  • 1,880.19CNY

  • Detail
  • USP

  • (1285851)  Flutamide  United States Pharmacopeia (USP) Reference Standard

  • 13311-84-7

  • 1285851-200MG

  • 4,326.66CNY

  • Detail
  • Sigma

  • (F9397)  Flutamide  

  • 13311-84-7

  • F9397-1G

  • 402.48CNY

  • Detail
  • Sigma

  • (F9397)  Flutamide  

  • 13311-84-7

  • F9397-5G

  • 1,363.05CNY

  • Detail

13311-84-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name flutamide

1.2 Other means of identification

Product number -
Other names 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:13311-84-7 SDS

13311-84-7Synthetic route

N-(3-iodo-4-nitrophenyl)isobutyramide
1456616-25-3

N-(3-iodo-4-nitrophenyl)isobutyramide

trimethylsilyl 2-chloro-2,2-difluoroacetate

trimethylsilyl 2-chloro-2,2-difluoroacetate

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
With copper(l) iodide; N,N,N,N,-tetramethylethylenediamine; silver fluoride In N,N-dimethyl-formamide at 100℃; Sealed tube; Inert atmosphere;99%
4-bromo-1-nitro-2-(trifluoromethyl)benzene
344-38-7

4-bromo-1-nitro-2-(trifluoromethyl)benzene

potassium (2-methyl-1-((trimethylsilyl)oxy)propylidene)amide

potassium (2-methyl-1-((trimethylsilyl)oxy)propylidene)amide

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
Stage #1: potassium (2-methyl-1-((trimethylsilyl)oxy)propylidene)amide With tris-(dibenzylideneacetone)dipalladium(0); XPhos In 1,4-dioxane at 100℃; for 0.166667h;
Stage #2: 4-bromo-1-nitro-2-(trifluoromethyl)benzene In 1,4-dioxane at 100℃; for 16h;
86%
2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide
1939-27-1

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
With sulfuric acid; nitric acid at -5℃; for 3h;83.3%
With sulfuric acid; nitric acid at 0 - 5℃; for 3h;79%
With 3-(ethoxycarbonyl)-1-(5-methyl-5-(nitrosooxy)hexyl)pyridin-1-ium bis(trifluoromethanesulfonyl)imide at 20℃; for 5h; Ionic liquid;69%
ISOPROPYLAMIDE
563-83-7

ISOPROPYLAMIDE

3-trifluoromethyl-4-nitrophenol
88-30-2

3-trifluoromethyl-4-nitrophenol

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
With 6Zr(4+)*4O(2-)*6C14H8N2O4(2-)*4HO(1-) In tetrahydrofuran at 70℃; for 24h; Molecular sieve; Sealed tube; Inert atmosphere;53%
4-nitro-3-(trifluoromethyl)benzeneamine
393-11-3

4-nitro-3-(trifluoromethyl)benzeneamine

isobutyryl chloride
79-30-1

isobutyryl chloride

Flutamide
13311-84-7

Flutamide

3-trifluoromethylaniline
98-16-8

3-trifluoromethylaniline

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: cyanuric chloride; N-methylmorpholine / CH2Cl2 / 5 h / 0 - 5 °C
1.2: 20.0 g / CH2Cl2 / 3 h / 20 °C
2.1: 79 percent / sulfuric acid; nitric acid / 3 h / 0 - 5 °C
View Scheme
α,α,α-trifluorotoluene
98-08-8

α,α,α-trifluorotoluene

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sulfuric acid; nitric acid / 3 h / 20 °C
2: iron / 4 h / Reflux; Inert atmosphere
3: sulfuric acid; nitric acid / 3 h / 0 - 5 °C
View Scheme
2,4-diaminonitrobenzene
5131-58-8

2,4-diaminonitrobenzene

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: dmap / dichloromethane / 20 °C
2: isopentyl nitrite; copper(l) iodide / acetonitrile / 0 - 20 °C
3: copper(l) iodide; silver fluoride; N,N,N,N,-tetramethylethylenediamine / N,N-dimethyl-formamide / 100 °C / Sealed tube; Inert atmosphere
View Scheme
N-(3-amino-4-nitrophenyl)isobutyramide

N-(3-amino-4-nitrophenyl)isobutyramide

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: isopentyl nitrite; copper(l) iodide / acetonitrile / 0 - 20 °C
2: copper(l) iodide; silver fluoride; N,N,N,N,-tetramethylethylenediamine / N,N-dimethyl-formamide / 100 °C / Sealed tube; Inert atmosphere
View Scheme
4-nitro-3-(trifluoromethyl)benzeneamine
393-11-3

4-nitro-3-(trifluoromethyl)benzeneamine

Thioisobutyric acid S-pyridin-2-yl ester
81357-56-4

Thioisobutyric acid S-pyridin-2-yl ester

Flutamide
13311-84-7

Flutamide

Conditions
ConditionsYield
With sodium hydride In tetrahydrofuran at 20℃; for 2h; Glovebox; Inert atmosphere; Sealed tube;15.4 mg
Flutamide
13311-84-7

Flutamide

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide
39235-51-3

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With borane-ammonia complex; jacquesdietrichite In d(4)-methanol; water-d2 at 20℃; for 1h;99%
With hydrogen; triethylamine In ethanol; water at 110℃; under 30003 Torr; for 21h; Autoclave;97%
With hydrogen; triethylamine In ethanol; water at 110℃; under 30003 Torr; for 21h; Autoclave;97%
Flutamide
13311-84-7

Flutamide

bromoacetic acid methyl ester
96-32-2

bromoacetic acid methyl ester

methyl N-isobutyryl-N-(4-nitro-3-(trifluoromethyl)phenyl)glycinate

methyl N-isobutyryl-N-(4-nitro-3-(trifluoromethyl)phenyl)glycinate

Conditions
ConditionsYield
Stage #1: Flutamide With sodium hydride In N,N-dimethyl-formamide for 0.75h; Inert atmosphere; Cooling with ice;
Stage #2: bromoacetic acid methyl ester In N,N-dimethyl-formamide at 20℃; for 24h; Inert atmosphere;
95%
methanol
67-56-1

methanol

Flutamide
13311-84-7

Flutamide

C13H17F3N2O

C13H17F3N2O

Conditions
ConditionsYield
With aluminum (III) chloride; water In acetonitrile at 20℃; for 18h; Irradiation;90%
Flutamide
13311-84-7

Flutamide

C18H25BO8

C18H25BO8

C29H35F3N2O9S

C29H35F3N2O9S

Conditions
ConditionsYield
With sodium metabisulfite; lithium phosphate; choline chloride In N,N-dimethyl-formamide at 130℃; for 10h; Inert atmosphere;77%
Flutamide
13311-84-7

Flutamide

C18H25BO8

C18H25BO8

N-(4-((4-(((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methoxy)phenyl)sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

N-(4-((4-(((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methoxy)phenyl)sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

Conditions
ConditionsYield
With sodium metabisulfite; lithium phosphate; choline chloride; water In N,N-dimethyl-formamide at 130℃; for 10h; Schlenk technique; Inert atmosphere;77%
Flutamide
13311-84-7

Flutamide

4-Chlorophenylboronic acid
1679-18-1

4-Chlorophenylboronic acid

N-(4-((4-chlorophenyl)sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

N-(4-((4-chlorophenyl)sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

Conditions
ConditionsYield
With 1,10-Phenanthroline; tetrakis(actonitrile)copper(I) hexafluorophosphate; potassium pyrosulfite; isopropyl alcohol at 70℃; for 48h; Sealed tube; Inert atmosphere;75%
With 1,10-Phenanthroline; potassium pyrosulfite; tetrakis(acetonitrile)copper(I) hexafluorophosphate In 1-methyl-pyrrolidin-2-one; isopropyl alcohol at 70℃; for 48h; Inert atmosphere; Sealed tube;
ethanol
64-17-5

ethanol

Flutamide
13311-84-7

Flutamide

C15H21F3N2O

C15H21F3N2O

Conditions
ConditionsYield
With aluminum (III) chloride; water In acetonitrile at 20℃; Irradiation;72%
thiophene boronic acid
6165-68-0

thiophene boronic acid

Flutamide
13311-84-7

Flutamide

N-(4-(thiophene-2-sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

N-(4-(thiophene-2-sulfonamido)-3-(trifluoromethyl)phenyl)isobutyramide

Conditions
ConditionsYield
With potassium pyrosulfite; tetrabutyl-ammonium chloride; potassium carbonate In acetonitrile at 130℃; for 24h; Sealed tube;69%
methanol
67-56-1

methanol

Flutamide
13311-84-7

Flutamide

C12H15F3N2O

C12H15F3N2O

Conditions
ConditionsYield
With aluminum (III) chloride; water In acetonitrile at 20℃; for 11.5h; Irradiation;50%
Flutamide
13311-84-7

Flutamide

A

4-nitro-3-(trifluoromethyl)benzeneamine
393-11-3

4-nitro-3-(trifluoromethyl)benzeneamine

B

N-[4-amino-3-(trifluoromethyl)phenyl]acetamide
1579-89-1

N-[4-amino-3-(trifluoromethyl)phenyl]acetamide

C

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide
39235-51-3

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With Rhodotorula mucilaginosa (ATCC 20129) In N,N-dimethyl-formamide at 20℃; for 336h; Physiological pH; Microbiological reaction;A 11.1%
B 3%
C 3.3%
Flutamide
13311-84-7

Flutamide

A

4-nitro-3-(trifluoromethyl)benzeneamine
393-11-3

4-nitro-3-(trifluoromethyl)benzeneamine

B

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

C

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With β‐cyclodextrin In phosphate buffer pH=7.4; Quantum yield; Irradiation;
With β‐cyclodextrin In phosphate buffer pH=7.4; Irradiation;
Flutamide
13311-84-7

Flutamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
In phosphate buffer pH=7.4; Quantum yield; Irradiation;
In phosphate buffer pH=7.4; Irradiation;
With water for 2h; pH=7.4; Quantum yield; UV-irradiation; Inert atmosphere; aq. phosphate buffer;
Flutamide
13311-84-7

Flutamide

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With benzenesulfonamide In phosphate buffer pH=7.4; Product distribution; Further Variations:; irradiation time; absence of regent; Irradiation;
With L-α-Phosphatidylcholine In various solvent(s) Quantum yield; Photolysis;
Multi-step reaction with 2 steps
1: water; ammonium chloride; zinc / methanol / 1.5 h
2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 °C
View Scheme
Flutamide
13311-84-7

Flutamide

4-nitro-3-(trifluoromethyl)benzeneamine
393-11-3

4-nitro-3-(trifluoromethyl)benzeneamine

Conditions
ConditionsYield
With sodium hydroxide at 25℃;
With sodium hydroxide In ice-water; ethanol
With hydrogenchloride In methanol; water at 100℃; for 0.4h; Kinetics; Activation energy; Reagent/catalyst; Temperature; pH-value;
With sodium hydroxide In methanol; water at 80℃; for 3h; Kinetics; Activation energy; Reagent/catalyst; Temperature; Concentration;
phosphorous pentasulfide

phosphorous pentasulfide

Flutamide
13311-84-7

Flutamide

4'-Nitro-3'-trifluoromethylisobutyrthioanilide
39240-88-5

4'-Nitro-3'-trifluoromethylisobutyrthioanilide

Conditions
ConditionsYield
With sodium hydroxide; sulfuric acid In toluene; benzene
With sodium hydroxide; sulfuric acid In toluene; benzene
Flutamide
13311-84-7

Flutamide

A

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

B

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-nitroso-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With water; bovine serum albumin Quantum yield; Reagent/catalyst; UV-irradiation; Inert atmosphere; aq. phosphate buffer;
Flutamide
13311-84-7

Flutamide

isopropyl alcohol
67-63-0

isopropyl alcohol

A

2,3-dimethyl-2,3-butane diol
76-09-5

2,3-dimethyl-2,3-butane diol

B

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide
1939-27-1

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide

Conditions
ConditionsYield
Irradiation; High pressure;
Flutamide
13311-84-7

Flutamide

isopropyl alcohol
67-63-0

isopropyl alcohol

A

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide
1939-27-1

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide

B

1-methylethyl 2-amino-5-(2-methylpropanamido)benzoate

1-methylethyl 2-amino-5-(2-methylpropanamido)benzoate

C

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide
39235-51-3

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide

D

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With oxygen Irradiation; High pressure;
Flutamide
13311-84-7

Flutamide

A

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide
1939-27-1

2-methyl-N-[3-(trifluoromethyl)phenyl]propionamide

B

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide
39235-51-3

2-methyl-N-[4-amino-3-(trifluoromethyl)phenyl]propanamide

C

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With oxygen In acetonitrile Irradiation; High pressure;
Flutamide
13311-84-7

Flutamide

A

N-[4-hydroxy 3-nitro-5-(trifluoromethyl)phenyl]-2-methylpropanamide

N-[4-hydroxy 3-nitro-5-(trifluoromethyl)phenyl]-2-methylpropanamide

B

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

2-methyl-N-[4-hydroxy-3-(trifluoromethyl)phenyl]propanamide

Conditions
ConditionsYield
With oxygen In acetonitrile Irradiation; High pressure;
Flutamide
13311-84-7

Flutamide

1-methylethyl 2-amino-5-(2-methylpropanamido)benzoate

1-methylethyl 2-amino-5-(2-methylpropanamido)benzoate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ammonium chloride; zinc / methanol / 1 h / 20 °C
2: 0.03 h / Irradiation; High pressure
View Scheme
Flutamide
13311-84-7

Flutamide

N-[4-hydroxy 3-nitro-5-(trifluoromethyl)phenyl]-2-methylpropanamide

N-[4-hydroxy 3-nitro-5-(trifluoromethyl)phenyl]-2-methylpropanamide

Conditions
ConditionsYield
In acetonitrile Irradiation; High pressure;43 mg

13311-84-7Relevant academic research and scientific papers

A novel method for synthesis of flutamide on the bench-scale

Ghaffarzadeh, Mohammad,Rahbar, Sahar

, p. 200 - 201 (2014)

Flutamide has been synthesised conveniently in high yields and by an economically beneficial method. Benzotrifluoride was first nitrated and the product was reduced and acylated in one pot in the presence of iron powder and isobutyric acid to produce 3-trifluoroisobutyranilide. Finally, flutamide was produced by further nitration.

A Nickel(II)-Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides

Pedersen, Simon S.,Donslund, Aske S.,Mikkelsen, Jesper H.,Bakholm, Oskar S.,Papp, Florian,Jensen, Kim B.,Gustafsson, Magnus B. F.,Skrydstrup, Troels

, p. 7114 - 7123 (2021)

A series of pharmaceutically relevant small molecules and biopharmaceuticals bearing aliphatic carboxamides have been successfully labeled with carbon-13. Key to the success of this novel carbon isotope labeling technique is the observation that 13C-labeled NiII-acyl complexes, formed from a 13CO insertion step with NiII-alkyl intermediates, rapidly react in less than one minute with 2,2’-dipyridyl disulfide to quantitatively form the corresponding 2-pyridyl thioesters. Either the use of 13C-SilaCOgen or 13C-COgen allows for the stoichiometric addition of isotopically labeled carbon monoxide. Subsequent one-pot acylation of a series of structurally diverse amines provides the desired 13C-labeled carboxamides in good yields. A single electron transfer pathway is proposed between the NiII-acyl complexes and the disulfide providing a reactive NiIII-acyl sulfide intermediate, which rapidly undergoes reductive elimination to the desired thioester. By further optimization of the reaction parameters, reaction times down to only 11 min were identified, opening up the possibility of exploring this chemistry for carbon-11 isotope labeling. Finally, this isotope labeling strategy could be adapted to the synthesis of 13C-labeled liraglutide and insulin degludec, representing two antidiabetic drugs.

3-(Ethoxycarbonyl)-1-(5-methyl-5-(nitrosooxy)hexyl)pyridin-1-ium cation: A green alternative to tert-butyl nitrite for synthesis of nitro-group-containing arenes and drugs at room temperature

Chaudhary, Renu,Natarajan, Palani,Rani, Neetu,Sakshi,Venugopalan, Paloth

supporting information, (2019/12/30)

Due to their remarkable properties, task-specific ionic liquids have turned out to be progressively popular over the last few years in the field of green organic synthesis. Herein, for the first time, we report that a new task-specific nitrite-based ionic liquid such as 3-(ethoxycarbonyl)-1-(5-methyl-5-(nitrosooxy)hexyl)pyridin-1-ium bis(trifluoromethanesulfonyl)imides (TS-N-IL) derived from biodegradable ethyl nicotinate indeed acted as an efficient and eco-friendly reagent for the synthesis of highly valuable nitroaromatic compounds and drugs including nitroxynil, tolcapone, niclofolan, flutamide, niclosamide and nitrazepam. The bridging of an ionic liquid with nitrite group not only increases the yield and rate of direct C[sbnd]N bond formation reaction but also allows easy product separation and recyclability of a byproduct. Nonvolatile nature, easy synthesis, merely stoichiometric need and mildness are a portion of the extra focal points of TS-N-IL while contrasted with tert-butyl nitrite an outstanding and highly-flammable reagent utilized largely in organic synthesis.

Synthesis method of drug intermediate flutamide

-

Paragraph 0008; 0010-0028, (2018/06/21)

The invention discloses a synthesis method of a drug intermediate flutamide. N-hexane, m-trifluoromethylaniline, isobutyric anhydride, NaOH, m-isobutyramidobenzotrifluoride, sodium hydrogen carbonateand ethyl orthosilicate are used as main raw materials; a method of combining a sol-gel method with calcination is utilized; SiO2 is used as a carrier; a perfluorosulfonic resin solution is directly dispersed on a porous SiO2 colloid serving as a skeleton; a mixing-ratio relation among raw materials is strictly explored; a catalyst for preparing the flutamide from the isobutyric anhydride, which has certain crystal form, grain size, pore structure and specific area and high mechanical strength is developed; the raw materials used by the synthesis method are according to the following mixing ratios in which a mass ratio of the isobutyric anhydride to the m-trifluoromethylaniline is 2 to 1, a volume ratio of the n-hexane to the NaOH is 2 to 1, and the volume ratio of concentrated sulfuric acid to concentrated nitric acid is 10 to 1; a preparation method of the flutamide has the characteristics of simpleness, easiness, feasibleness, short preparation period and the like, and the raw materials and the catalyst which are used in a technical process have high efficiency, wide application ranges and an excellent catalytic effect on the preparation of the flutamide from the isobutyric anhydride, are simple, convenient, quick and extremely environment-friendly, moreover, are easily recovered and can be regenerated.

TCDA: Practical Synthesis and Application in the Trifluoromethylation of Arenes and Heteroarenes

Wang, Jian,Zhang, Xiaomin,Wan, Zehong,Ren, Feng

, p. 836 - 839 (2016/05/19)

A practical synthesis of the reagent trimethylsilyl chlorodifluoroacetate (TCDA) is reported on 50 g scale. The trifluoromethylation with TCDA was optimized, and the reaction shows very broad scope with respect to electron-deficient, -neutral, -rich aryl/heteroaryl iodides, as well as excellent functional group tolerability, such as ester, amide, aldehyde, hydroxyl, and carboxylic acid. The reagent was also applied to the late-stage trifluoromethylation of three medicinally relevant compounds. Additionally, the building block trifluoromethylpyridine and one drug related molecule Boc-Fluoxetin were synthesized in 10 g scale by this method, demonstrating its practical applications in process chemistry.

Palladium-Catalyzed Synthesis of Aryl Amides through Silanoate-Mediated Hydrolysis of Nitriles

McPherson, Christopher G.,Livingstone, Keith,Jamieson, Craig,Simpson, Iain

supporting information, p. 88 - 92 (2015/12/26)

A procedure for the formation of aryl amides through the palladium-catalyzed coupling of nitriles and aryl bromides, via the formation of intermediary silanoate derived imidate species is reported. Optimization was undertaken and examples of the process are described that furnish the products in up to 86% isolated yield.

Mild and Efficient Cobalt-Catalyzed Cross-Coupling of Aliphatic Amides and Aryl Iodides in Water

Tan, Bryan Yong-Hao,Teo, Yong-Chua

supporting information, p. 1697 - 1701 (2015/07/20)

A convenient protocol for the C-N cross-coupling of aliphatic amides and iodobenzene is demonstrated using a simple and inexpensive Co(C2O4)·2H2O/N,N′-dimethylethylenediamine (DMEDA) catalytic system in water. Good yields of N-arylated products were isolated (up to 85%) and the protocol has been successfully applied to the synthesis of the anticancer drug, flutamide.

An azobenzene-containing metal-organic framework as an efficient heterogeneous catalyst for direct amidation of benzoic acids: Synthesis of bioactive compounds

Hoang, Linh T. M.,Ngo, Long H.,Nguyen, Ha L.,Nguyen, Hanh T. H.,Nguyen, Chung K.,Nguyen, Binh T.,Ton, Quang T.,Nguyen, Hong K. D.,Cordova, Kyle E.,Truong, Thanh

supporting information, p. 17132 - 17135 (2015/12/04)

An azobenzene-containing zirconium metal-organic framework was demonstrated to be an effective heterogeneous catalyst for the direct amidation of benzoic acids in tetrahydrofuran at 70°C. This finding was applied to the synthesis of several important, representative bioactive compounds.

PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS

-

, (2014/03/24)

This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.

THERAPEUTIC FOR HEPATIC CANCER

-

, (2011/02/18)

A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 13311-84-7